Medications & hormones

Aromatase inhibitor, recorded alongside testosterone protocols where oestradiol management is part of the plan.

A selective androgen receptor modulator whose development was abandoned due to vision side effects.

Omeprazole and similar. Relevant beyond the symptom: sustained acid suppression reduces absorption of magnesium, B12 and iron.

A placeholder for whatever you were prescribed, so the course is on the timeline without needing a catalogue entry per drug. Rename it to the actual antibiotic.

Cetirizine, loratadine and similar. Seasonal use is worth logging — allergy load itself affects sleep and training quality.

NSAID, and an irreversible platelet inhibitor. The antiplatelet effect lasts the life of the platelet, roughly a week, long after the drug itself has cleared.

A statin that lowers LDL cholesterol by blocking an early step of hepatic cholesterol synthesis.

An anabolic steroid developed for veterinary use that was never FDA-approved for human medicine.

An FDA-approved dopamine agonist used to treat hyperprolactinemic disorders.

Long-acting amylin agonist that adds synergistic weight loss on top of GLP-1 drugs.

An FDA-approved selective estrogen receptor modulator used to induce ovulation in women with infertility.

An adrenal steroid precursor to estrogens and androgens, sold over the counter and studied separately in a prescription vaginal form.

Topical NSAID for a specific joint or muscle. Systemic exposure is a fraction of oral, which is the point.

An anabolic steroid approved for palliative treatment of advanced breast cancer in postmenopausal women.

An FDA-approved 5-alpha reductase inhibitor for benign prostatic hyperplasia, used off-label for hair loss.

The active isomer of clomiphene with potential for raising testosterone while preserving fertility, but not FDA-approved.

An FDA-approved steroidal aromatase inhibitor used to treat hormone receptor-positive breast cancer.

An FDA-approved 5-alpha reductase inhibitor used to treat benign prostatic hyperplasia.

A peroxisome proliferator-activated receptor agonist that was never approved for human use.

Placental hormone that mimics LH to stimulate testicular testosterone production and sperm output. Used clinically for hypogonadism/fertility, off-label in TRT, and in doping.

NSAID. Regular use around training suppresses the inflammatory signal that drives adaptation, so a week of it is worth seeing next to your training log.

A long-acting basal insulin analogue for once-daily use in type 1 and type 2 diabetes.

An FDA-approved aromatase inhibitor used to treat hormone receptor-positive breast cancer.

Synthetic T4. Absorption is materially reduced by calcium, iron and magnesium, so timing separation is part of the protocol.

A selective androgen receptor modulator investigated in clinical trials but not FDA-approved for human use.

Synthetic T3. Short half-life, so it is often split across the day rather than taken once.

First-generation GLP-1 receptor agonist, FDA-approved for weight loss (Saxenda) and diabetes (Victoza) with well-established safety and efficacy.

Dual GLP-1/glucagon agonist in Phase 3 trials showing 15-20% weight loss with metabolic benefits beyond weight reduction.

An anabolic steroid used clinically to treat male hypogonadism and low testosterone.

A biguanide that lowers blood glucose by reducing hepatic glucose output, first-line for type 2 diabetes.

An anabolic steroid whose FDA approval was revoked in 1985 and is no longer approved for human use.

An anabolic steroid with limited clinical use and documented risks of androgenic and hepatic toxicity.

An FDA-approved topical medication for pattern hair loss that extends the hair growth phase and increases follicle size.

A selective androgen receptor modulator tested in over 1,700 subjects that failed FDA approval for muscle wasting.

Orally active ghrelin mimetic that raises growth hormone and IGF-1 without injections. Not actually a peptide, but a fixture of GH-secretagogue discussions.

Long-acting 19-nortestosterone ester. Suppresses natural production and is detectable long after use.

Longer-acting NSAID, typically twice daily rather than every few hours.

Oestrogen used in feminising HRT and menopausal HRT. Available as tablets, patches, gel and injectable esters.

Electrolyte replacement for illness, heat or heavy sweating.

An oral small-molecule GLP-1 receptor agonist showing 10-11% weight loss in Phase III trials, pending regulatory approval in 2026.

An anabolic steroid FDA-approved for protein catabolism secondary to corticosteroids and osteoporosis-related bone pain.

An FDA-approved anabolic steroid used to treat anemias caused by deficient red-cell production.

The 'bonding hormone' — an FDA-approved drug for labor induction and postpartum hemorrhage, explored off-label for social bonding, sexual intimacy and anxiety.

Analgesic and antipyretic, not an anti-inflammatory. The usual choice when you want pain or fever relief without suppressing inflammation.

An FDA-approved medication for interstitial cystitis that restores bladder protective layer, with risk of vision changes from long-term use.

A cholesterol-derived steroid precursor to progesterone and DHEA, sold as an unregulated supplement.

Bioidentical progesterone used in HRT. Oral dosing is sedating, which is why it is usually taken at night.

A selective androgen receptor modulator with preclinical promise but limited human data and reported serious adverse effects.

An FDA-approved phosphodiesterase-5 inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension.

FDA-approved recombinant growth hormone for deficiency, widely used off-label for performance and body composition.

A REV-ERB agonist research compound with significant off-target effects that is not FDA-approved.

A synthetic anabolic steroid that was FDA-approved for hereditary angioedema but is now discontinued.

Boehringer Ingelheim's GLP-1/glucagon dual agonist in Phase 3, showing 17-22% weight loss with a cardiovascular outcomes trial underway.

Blend of four testosterone esters with staggered release, from fast-acting propionate to slow decanoate.

An FDA-approved phosphodiesterase-5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary hypertension.

An FDA-approved selective estrogen receptor modulator used to treat hormone receptor-positive breast cancer.

FDA-approved PTH analog that stimulates bone formation. Used clinically for osteoporosis and investigationally for stress fractures and fracture healing.

A neurotransmitter reuptake inhibitor showing significant weight loss in Phase II and III trials.

Long-acting testosterone ester, half-life around eight days, which is why weekly or twice-weekly injection is typical.

The longest-acting ester in Sustanon, qualitatively between enanthate and undecanoate but never marketed or studied on its own.

Long-acting testosterone ester with a half-life close to cypionate. Largely interchangeable for scheduling.

Daily transdermal testosterone, dosed by pump actuations or sachets rather than injection volume.

A mid-length testosterone ester that only ever appears as one component of a blend such as Sustanon.

A mid-length testosterone ester, almost always used as one component of a blend such as Sustanon rather than on its own.

Short-acting testosterone ester, half-life around two to three days, requiring frequent injection.

A long-acting testosterone ester, given as an intramuscular depot or an oral capsule, for confirmed male hypogonadism.

A synthetic anabolic steroid with no approved human indication and extensive reports of severe adverse effects.

A research compound investigated for male contraception that never received FDA approval.

An anabolic steroid with historical use in East German doping programs and no modern approved indication.

An experimental selective androgen receptor modulator with myostatin-inhibiting properties and documented neurological risks.